IGMS - IGM Biosciences - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

461.3M

Cash

293.8M

Avg Qtr Burn

-45.91M

Short % of Float

48.39%

Insider Ownership

34.45%

Institutional Own.

68.39%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Imvotamab (IGM-2323) (CD20 x CD3) Details Systemic lupus erythematosus, Autoimmune disease	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imvotamab (IGM-2323) (CD20 x CD3) Details Autoimmune disease, Rheumatoid arthritis	Phase 1b Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imvotamab (IGM-2323) (CD20 x CD3) Details Idiopathic inflammatory myopathy / myositis	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Aplitabart (IGM-8444) (DR5 agonist) + FOLFIRI +/- bevacizumab Details Cancer, Solid tumor/s, Colorectal cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IGM-7354 (IL-15 x PD-L1) Details Solid tumor/s, Cancer, Hematologic malignancies	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Aplitabart (IGM-8444) + venetoclax & azacytidine Details Acute myeloid leukemia	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Aplitabart (IGM-8444) + birinapant Details Hematologic malignancies, Solid tumor/s	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IGM-2644 (CD38 x CD3) Details Multiple myeloma	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Imvotamab (IGM-2323) (CD20 x CD3) Details Cancer, Chronic lymphocytic leukemia, Non-Hodgkin lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IGM-6268 Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.